[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Trieste\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":240},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,50,85,107,132,156,187,209],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100598579","effects-of-normobaric-hypoxic-training-in-metabolic-dysfunction-associated-steatotic-liver-disease-masld-100598579",false,"NCT07073326","Effects of Normobaric Hypoxic Training in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","Effects of Normobaric Hypoxia Aerobic Training in People With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","HYPOMASLD","Inclusion Criteria:\n\n* Being diagnosed with MASLD from at the least 3 years\n* BMI \\> 26 kg\u002Fm2\n* Being sedentary\n\nExclusion Criteria:\n\n* Cardiovascular, respiratory, renal complications\n* Hypertension\n* COPD\n* Previous history of acute mountain sickness or altitude-associated symptoms\n* Females only: pregnancy or breastfeeding","ALL","18 Years","50 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"NA","Altitude training has been suggested to be of potential support to improve some chronic clinical conditions, especially metabolic conditions. Normobaric hypoxia represents a promising system to simulate altitude training, and its efficacy and safety have been suggested in different conditions, including diabetes, obesity and hypertension. Metabolic dysfunction-associated steatotic liver disease (MASLD) can characterized by metabolic alterations (including altered body composition, lipid and glycemic profile, etc.), and might benefit from aerobic training performed in simulated altitude training (i.e., normobaric hypoxia). Mild altitude training will be proposed (equal to about 2'500 m, 15% FiO2) and compared to a sham normobaric normoxia condition, during an 8-week 3 or 2 times per week 1-h aerobic training (walking) at 60-65% of maximum heart rate (HRmax). Cardiorespiratory fitness, body composition, and metabolic profile will be investigated.",[28,29],"MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","Normobaric Hypoxia",[31,32,33,34,35,36],"Hypoxia","Altitude","Exercise","Liver","Metabolism","Fat","RECRUITING","2026-04-27",{"date":40,"type":41},"2026-05-04","ACTUAL",{"date":43,"type":41},"2025-09-01",{"date":45,"type":22},"2026-07",{"name":47,"class":48},"University of Trieste","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},"100626008","phase-2-repurposing-mirtazapine-in-rett-syndrome-100626008","NCT07430046","Repurposing Mirtazapine in Rett Syndrome","Repurposing Mirtazapine in Rett Syndrome: a Multicentric Open Label Phase II Study","MirtaRett","INCLUSION CRITERIA\n\n* 1\\. Female aged 5 to 39 years inclusive, at the time of signing the informed consent.\n* 2\\. Girls of childbearing age negative to pregnancy test;\n* 3\\. Body weight \\> 10 kg. and within the expected range for RTT, based on age and height.\n* 4\\. Diagnosis of RTT based on consensus clinical criteria (Neul, 2010) and a confirmed mutation in MECP2 gene.\n* 5\\. Breathing dysfunction (at least one of the following): period apnoea, intermittent hyperventilation, breath holding spells, air swallowing, forced expulsion of air and \u002For saliva.\n* 6\\. Ten episodes or more\u002Fday of breathing dysfunction during wakefulness in the week prior to the screening visit (parents report).\n\n  7\\. Stable medication regimen for 4 weeks prior to beginning the study (if receiving services - physical, occupational, or speech therapy - subjects must be on a stable regimen of these services for 3 months prior to beginning the study).\n* 8\\. Female patients of childbearing potential must use a highly effective contraceptive method such as combined hormonal contraception (containing estrogen and progestin) associated with ovulation suppression (oral, intravaginal, transdermal); progestin-only hormonal contraception associated with ovulation suppression (oral, injectable, implantable); intrauterine device; hormone-releasing intrauterine system. Sexual abstinence is considered a highly effective contraceptive method if it aligns with the individual's usual lifestyle. Female patients of childbearing potential are to use adequate contraception as recommended by their Health Care Provider.\n* 9\\. Written consent signed by parent\u002Flegal guardian\u002Frepresentative prior to screening visit\n* 10\\. Patient is cooperative, willing to complete the study, and capable of doing so with assistance of a caregiver.\n* 11\\. Caregiver is able to understand the instructions and fully participate.\n\nEXCLUSION CRITERIA\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n* Patient is participating to another investigational clinical trial.\n* Hypersensitivity to MTZ or any of the other ingredients of Mirtapil®.\n* Clinically significant (as determined by the investigator) cardiovascular, respiratory, gastrointestinal, renal, hepatic, haematological pathologies or other pathologies, in addition to those directly related to RTT. In particular, patients with the following parameters will be excluded: leucocyte count is \\\u003C 4000\u002Fmm2; neutrophil count is \\\u003C 2000\u002Fmm3; hyponatremia (\\\u003C 125 mmol\u002FL); renal dysfunction (creatinine \\> 2 X ULN), hepatic dysfunction (AST, ALT, bilirubin \\> 2 X ULN); or if severe diabetes mellitus is present.\n* QTcF interval on the ECG greater than 450 msec\n* Surgery planned during the study.\n* Severe diabetes mellitus (hyperglycaemia with values above 250\u002F300 mg\u002FdL);\n* Pregnancy, breastfeeding.\n* Evidence of clinically significant malnutrition with BMI (or BMI) (kg\u002Fm2) \\\u003C\n* Patients who manifested prior suicidal ideation.","FEMALE","5 Years","40 Years",{"count":62,"type":22},54,[64],"PHASE2","Rett Syndrome (RTT) is a rare neurodevelopmental disorder caused by an MECP2 gene mutation on the X chromosome, primarily affecting females. It causes progressive motor and cognitive decline, loss of speech, repetitive hand movements, breathing issues, seizures, and sleep problems. Given RTT's association with reduced monoamine levels, antidepressants like mirtazapine (MTZ) may help.Preclinical studies in MeCP2-mutant mice and early adult RTT trials showed that MTZ improved respiratory, motor, and neurological function, sleep, and mood, prompting this pediatric and young adult study. The MirtaRett trial is a multicenter, open-label, single-arm, phase II study enrolling 54 female RTT patients (ages 5-40), divided into groups of 18 (5-10, 11-17, 18-40 years). It aims to evaluate MTZ's safety and efficacy for mood, sleep, and motor symptoms, particularly hand control. Other ares of investigation include autonomic function, behavior, caregiver burden, clinical severity, and neuronal plasticity and metabolic biomarkers. Patients will receive escalating doses of MTZ oral solution: initial low doses (3.75-15 mg\u002Fday) for two weeks, followed by optimal doses (7.5-30 mg\u002Fday) for six months. Safety, tolerability, and symptoms will be monitored over 10 months (3-month screening, 6-month treatment, 1-month follow-up). The study is conducted at four Italian RTT-specialized hospitals, led by the University of Trieste. Partner sites are in Italy, specifically at the hospitals in Milan, Genova, Siena, and Messina.",[67],"RETT Syndrome With Proven MECP2 Mutation",[69,70,71,72,73,74,75],"antidepressant","mirtazapine","motor dysfunction","cognitive impairment","sleep disorder","cognitive disability","parent stress","2026-02-17",{"date":78,"type":41},"2026-02-24",{"date":80,"type":41},"2025-07-09",{"date":82,"type":22},"2026-12-31",{"name":47,"class":48},4,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":49},"100603977","comparison-of-the-sensibility-of-swept-source-optical-coherence-tomography-devices-in-the-detection-of-neovascularisation-in-large-pigment-epithelium-detachments-100603977","NCT07143526","Comparison of the Sensibility of Swept Source Optical Coherence Tomography Devices in the Detection of Neovascularisation in Large Pigment Epithelium Detachments","Comparison of Two Swept-source Optical Coherence Tomography Angiography (OCTA) Devices (Bmizar and Plexelite) for Detecting Macular Neovascularisation With Large (More Than 250 Microns) Pigment Epithelium Detachment (PED) in Age Related Macular Degeneration","Inclusion Criteria:\n\n* Patients treated for neovascular age related macular degeneration (AMD)\n* Presence of a pigmentary epithelium detachment higher than 250 microns measured on structural optical coherence tomography (OCT)\n\nExclusion Criteria:\n\n* Poor image quality or signal strength\n* Undefined retina layers",{"count":93,"type":22},50,"OBSERVATIONAL","The goal of this observational study is to compare swept source optical coherence tomography devices ability to detect macular neovascularisation when there is a large pigment epithelium detachment higher than 250 microns",[97],"AMD - Age-Related Macular Degeneration","NOT_YET_RECRUITING","2025-08-19",{"date":101,"type":41},"2025-08-27",{"date":103,"type":22},"2025-08",{"date":105,"type":22},"2025-09",{"name":47,"class":48},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":17,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":131,"locationsCount":49},"100598484","focusing-the-shoulder-or-considering-the-whole-body-in-volleyball-physiotherapy-100598484","NCT07072091","Focusing the Shoulder or Considering the Whole-Body in Volleyball Physiotherapy","Focusing the Shoulder or Considering the Whole-Body? A Randomized Controlled Trial on Physiotherapy Protocols for the Painful Shoulder in Volleyball Players","FocusVolley","Inclusion Criteria:\n\n* practicing volleyball for at least 5 years with a training volume of minimum 5 h\u002Fwk\n\nExclusion Criteria:\n\n* history of previous surgical intervention or fractures on the shoulder or spine",true,"17 Years","30 Years",{"count":119,"type":22},40,[25],"Shoulder pain can be common in overhead sports, and in particular, in volleyball. Different physiotherapy protocols can be adopted depending on the suspected pathophysiological mechanisms. Despite most of the protocols rely only on the shoulder district, some research suggests that treating the whole-body might produce better results as it could influence kinematic chains and correct muscle imbalances. The aim of this study will be to compare the effects of two physiotherapy protocols (shoulder focus or whole body) compared to only education without physiotherapy.",[123,124],"Shoulder Pain","Volleyball Players","2025-08-11",{"date":127,"type":41},"2025-08-14",{"date":129,"type":41},"2025-07-20",{"date":105,"type":22},{"name":47,"class":48},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":49},"100593448","at-home-treatment-with-cortico-spinal-tdcs-for-amyotrophic-lateral-sclerosis-100593448","NCT07006571","At-home Treatment With Cortico-spinal tDCS for Amyotrophic Lateral Sclerosis","Evaluation of the Efficacy of Home-based Transcranial Direct Current Stimulation on Physical Function in Patients With Amyotrophic Lateral Sclerosis: a Randomized, Controlled Clinical Trial","tDCS-ALS","Inclusion Criteria:\n\n* Male or female patients with a probable, laboratory-supported diagnosis of ALS, or defined ALS according to current clinical criteria\n* Age greater than 18 years\n* Onset of disease ≤ 24 months\n* Disease progression in the last 3 months\n* A score ≥ 2 on the \"respiratory failure\" item on the ALS Functional Rating Scale Revised (ALSFRS-R)\n* Treatment with riluzole or edaravone is permitted, provided it has been stable for at least 1 month prior to enrollment in the study, or no ALS-specific treatment\n* Presence of a caregiver who can assist the patient and who has successfully completed the necessary training in the use of the device\n* Signature of informed consent\n\nExclusion Criteria:\n\n* People with fixed electrical stimulators (e.g. cardiac pacemakers, nerve stimulators, hearing implants) that would not work or would be damaged by the electric field;\n* People with particular intracranial metal foreign bodies (e.g. splinters, some prostheses, screws and nails) that could interact with the electric field\n* People with a history of epilepsy;\n* As the effects of tDCS on the developing fetus are not known, pregnant women will be excluded from the study.",{"count":119,"type":22},[25],"Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that causes gradual muscle weakness and loss of muscle mass. It affects all muscles that control movement, speech, swallowing, and breathing. Unfortunately, ALS is currently incurable, and treatments are limited. Only two medications, riluzole and edaravone, have been approved and can slightly extend survival, typically between 20 and 48 months from diagnosis.\n\nRecent research has identified a useful biomarker known as neurofilament light chain (NfL), which increases in the blood as nerve cells become damaged. Measuring NfL levels can help track the progression of ALS.\n\nA promising non-invasive treatment called transcranial direct current stimulation (tDCS) has shown potential benefits for patients with ALS. tDCS involves safely applying mild electrical currents to specific areas of the brain and spinal cord. This approach aims to stimulate nerve cells, potentially improving their function and slowing disease progression. Initial studies have reported temporary improvements in muscle strength and survival when tDCS was used over a short period.\n\nBased on these encouraging results, our study proposes a new home-based tDCS treatment program specifically designed for ALS patients. Participants will use an easy-to-operate, safe, and portable device at home. The treatment involves placing electrodes on the scalp and the neck area to stimulate both the motor areas of the brain and the spinal cord. Therapy sessions will occur five days per week over 16 weeks.\n\nThis home-based approach allows patients to comfortably receive therapy without daily trips to the hospital, making treatment more accessible and convenient. By providing this therapy at home, the investigators aim to improve the quality of life for ALS patients and explore new possibilities in treating and managing ALS and other neurodegenerative diseases.",[144,145],"ALS","ALS (Amyotrophic Lateral Sclerosis)",[147,144,138],"At-home tDCS","2025-06-09",{"date":150,"type":41},"2025-06-13",{"date":152,"type":41},"2025-05-19",{"date":154,"type":22},"2029-09-30",{"name":47,"class":48},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":166,"conditions":167,"keywords":172,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":186},"100555785","fulminant-severe-cap---an-observational-study-100555785","NCT06516601","Fulminant Severe CAP - an Observational Study","Fulminant Cases Among Severe Community-acquired Pneumonia - an Observational Retrospective Study","FULMISCAP","Inclusion Criteria: severe community acquired pneumonia according to ATS\u002FIDSA -\n\nExclusion Criteria: incomplete outcome data\n\n\\-",{"count":165,"type":22},1460,"Severe community-acquired pneumonia (CAP) represents a major cause of hospital mortality. Among severe CAP cases, some exhibit a rapidly progressive evolution, leading to severe ARDS\u002Facute respiratory failure and septic shock within hours to a few days. This type of pneumonia, known as \"fulminant pneumonia,\" is characterized by its rapid onset and deterioration, often necessitating immediate medical intervention. Despite its severity, the true incidence and optimal treatment for fulminant pneumonia are not well understood. This knowledge gap is due to the lack of attention towards pneumonia as a potential time-dependent illness and the separation of overlapping clinical topics: severe pneumonia, ARDS, and sepsis.\n\nIn clinical practice, pneumonia is the most frequent cause of both ARDS and sepsis. However, these conditions are often considered separately, combining ARDS and sepsis from various extra-pulmonary causes with those originating from pneumonia. The COVID-19 pandemic, with its vast number of severe CAP cases in a short period, has highlighted the existence of fulminant pneumonias, underscoring the need for further investigation. Recent randomized clinical trials (RCTs) and experiences from COVID-19 have suggested that early and prolonged corticosteroid administration can reduce mortality in patients with severe SARS-CoV-2 infection and severe CAP\u002FARDS of bacterial origin.\n\nThe aim of this observational study is to analyze the rate of fulminant pneumonia and assess the impact of early corticosteroid treatment in a multicentric population of hospitalized patients with severe pneumonia.",[168,169,170,171],"Community-acquired Pneumonia","Severe Pneumonia","ARDS, Human","Sepsis",[173,174,175,176,177],"fulminant pneumonia","community acquired pneumonia","ARDS","sepsis","corticosteroids","2024-07-17",{"date":180,"type":41},"2024-07-24",{"date":182,"type":41},"2018-01-02",{"date":184,"type":22},"2024-10-01",{"name":47,"class":48},2,{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":23,"phases":196,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":49},"100541557","multiparametric-home-telemonitoring-of-patients-with-chronic-obstructive-pulmonary-disease-exacerbation-100541557","NCT06331416","Multiparametric Home Telemonitoring of Patients With Chronic Obstructive Pulmonary Disease Exacerbation","Inclusion Criteria:\n\n1. Able to understand and sign the informed consent form.\n2. Already established diagnosis of COPD according to Global Initiative for Obstructive Lung Disease (GOLD) guidelines.\\[13\\]\n3. Diagnosis of COPD exacerbation at admission, according to GOLD guidelines.\\[13\\]\n4. Arterial partial pressure of oxygen (PaO2) \\\u003C 60 mmHg in ambient air at rest at admission and arterial partial pressure of oxygen (PaO2) \\> 60 mmHg in ambient air at rest at discharge, if not on long-term oxygen therapy on ventilation.\n5. Arterial partial pressure of oxygen (PaO2) \\\u003C 55 mmHg on usual oxygen supplement (L\u002Fmin) and arterial partial pressure of oxygen (PaO2) \\> 60 mmHg on oxygen supplement at discharge, if already on long-term oxygen therapy on ventilation.\n\ng) Age \\\u003C= 90 and \\>= 18 years old at randomization.\n\nExclusion Criteria:\n\n1. Heart failure as the main cause of acute respiratory failure\n2. Acute pulmonary embolism\u002Fchronic pulmonary thromboembolism\n3. Interstitial lung disease as the main cause of acute respiratory failure\n4. Pneumonia as the main cause of acute respiratory failure\n5. Chronic renal failure with dialysis dependence\n6. Immunosuppression (i.e. cancer on treatment, post-organ transplantation, HIV-positive, on immunosuppressant therapy)\n7. Progressive neuro-muscular disorders\n8. Cognitively impaired, dementia or decompensated psychiatric disorder\n9. Quadriplegia\u002FHemiplegia or quadriparesis\u002Fhemiparesis\n10. Do-not-resuscitate order\n11. Any other condition that in the opinion of the investigator may significantly impact with patient's capability to comply with the protocol","90 Years",{"count":195,"type":22},60,[25],"Chronic obstructive pulmonary disease (COPD) exacerbations are risk factors for disease progression and short-term re- hospitalizations. We propose a randomized controlled trial to evaluate the efficacy of a one-device multiparameter telemonitoring in reducing functional decline, symptoms, and risk of re-hospitalization of patients discharged after hospitalization for exacerbated COPD.",[199,200],"COPD","COPD Exacerbation Acute","2024-04-30",{"date":203,"type":41},"2024-05-02",{"date":205,"type":41},"2024-03-29",{"date":207,"type":22},"2026-09-30",{"name":47,"class":48},{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":219,"conditions":220,"keywords":225,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":49},"100523647","biomarkers-in-the-diagnosis-and-prognosis-of-nafld-100523647","NCT06098417","Biomarkers in the Diagnosis and Prognosis of NAFLD","Identification of New Biomarkers in the Diagnosis and Prognosis of Non-alcoholic Fatty Liver Disease and Correlation With Ultrasound and Elastographic Findings","Inclusion Criteria:\n\nBMI\\> 35 Eligible for bariatric surgery according to the current international guidelines (IFSO guidelines)\n\nExclusion Criteria:\n\n* Patients affected by active liver viral infection\n* Patient alcohol or drug addicted\n* Incompetent patients","65 Years",{"count":218,"type":22},500,"Fibrosis is considered the leading cause of liver diseases and related mortality. Specifically, hepatic fibrosis is regarded as the consequence of reparative mechanisms initiated by hepatocytes in response to chronic damage. In Western countries, the main known etiologies include hepatitis (B and C), alcoholism, and non-alcoholic steatohepatitis (NASH). In particular, obesity is a determining factor in the onset and development of NASH. Alarming statistical data indicate that over 30% of the world's population is obese, and this eating disorder is increasingly affecting young people. NASH is a chronic disease that can present different degrees of fibrosis and, as the final stage, lead to the development of liver cirrhosis. Currently, the only accurate diagnostic and assessment system for this condition is liver biopsy, as there are no accurate non-invasive clinical tests available. The aim of this project is to identify (in silico) potential biomarkers involved in the development and progression of hepatic fibrosis and validate their presence and quantity in serum or plasma samples from obese patients (at-risk population). This would avoid the need for a liver biopsy and allow \"at-risk\" patients to undergo a simple ambulatory blood draw. Additionally, performing elastometry of the liver would allow for comparison of radiological results with laboratory findings.",[221,222,223,224],"NAFLD","Obesity","Liver Fibrosis","Diabetes Mellitus, Type 2",[226,222,227,228,229,230,231],"Nafld","Biomarkers","Liver ultrasound","Liver elastography","Bariatric surgery","Tissue biopsy","2023-10-18",{"date":234,"type":41},"2023-10-24",{"date":236,"type":41},"2015-09-22",{"date":238,"type":22},"2026-09-22",{"name":47,"class":48},""]